Keyphrases
BRCA Testing
11%
BRCA1, BRCA2
11%
Breast Cancer
22%
Breast Cancer Prevention
100%
Cancer Cases
11%
Cancer Prevention
11%
Cancer Risk
11%
Case-population
11%
Chemoprevention
11%
Comprehensive Genetic Testing
11%
Coronary Artery Disease
22%
Coronary Heart Disease Mortality
11%
Cost-effective Strategy
11%
Cost-effectiveness
100%
Early Intervention
11%
Economic Analysis
11%
Economic Evaluation
11%
Excess Mortality
11%
Family History
55%
Gene Testing
100%
Genetic Testing
11%
High-risk Individuals
11%
History Based
44%
In Cancer
11%
Incremental Cost
11%
Individualized Prediction
11%
Informed Decision-making
11%
Life-years Gained
11%
Magnetic Resonance Imaging
11%
Mammography
11%
Microsimulation Model
11%
Multigene Tests
11%
Ovarian Cancer
33%
Ovarian Cancer Screening
100%
PALB2
11%
Pathogenic Variants
33%
Payer Costs
11%
Payer Perspective
11%
Population-based
100%
Probabilistic Sensitivity Analysis
11%
Quality-adjusted Life Years
55%
Risk-reducing Mastectomy
11%
Salpingo-oophorectomy
11%
Standard of Care
11%
Testing Strategy
22%
Transformative Approach
11%
Willingness-to-pay Threshold
11%
Medicine and Dentistry
Base
12%
BRCA1
12%
BRCA2
12%
Breast Cancer
37%
Breast Cancer Prevention
100%
Cancer Prevention
12%
Cancer Risk
12%
Chemoprophylaxis
12%
Cost-Effectiveness Analysis
100%
Decision Making
12%
Early Intervention
12%
Family History
62%
Genetic Screening
25%
Health Care Cost
100%
Ischemic Heart Disease
37%
Lifespan
25%
Magnetic Resonance Imaging
12%
Mammography
12%
Mastectomy
12%
Ovarian Cancer
37%
Ovarian Cancer Prevention
100%
Quality Adjusted Life Year
62%
Salpingooophorectomy
12%